Excessive pregnancy weight gain may shape daughters’ ovarian and metabolic risk

Women who gain more weight during pregnancy than recommended may be setting up subtle hormonal and metabolic changes in their daughters that surface years later as polycystic ovary syndrome, now being renamed polyendocrine metabolic ovarian syndrome. That is the provocative hypothesis examined in a new review published in Frontiers in Endocrinology, which pulls together evidence from human cohort studies, animal experiments and placental biology to ask whether the scale reading at a prenatal checkup could echo through the next generation’s reproductive health.

The syndrome in question has long been known as polycystic ovary syndrome, a label the authors argue understates its scope. It is among the most common endocrine disorders affecting women of childbearing age, and the World Health Organization estimates that roughly 10 to 13 percent of women in that age group will develop it, with up to 70 percent of cases going undiagnosed for years. Its hallmarks include irregular menstrual cycles, anovulation, difficulty conceiving, excess hair growth, acne, obesity and elevated blood glucose driven by insulin resistance. The newer name, polyendocrine metabolic ovarian syndrome, reflects growing recognition that the condition involves multiple hormonal axes and systemic metabolic dysfunction rather than a purely ovarian problem, though most clinical criteria still use the older terminology.

What makes the review timely is its focus on a modifiable exposure: excessive gestational weight gain, defined as weight gain above the recommended range for a woman’s prepregnancy body mass index. The authors argue this is more than a number on a chart. In some pregnancies it travels with a cluster of metabolic disturbances, including insulin resistance, elevated insulin, altered lipid profiles, dysregulated adipokine secretion, chronic low-grade inflammation and oxidative stress. These changes could modify how the placenta transfers nutrients and hormones to the fetus, reshaping the developmental environment during critical windows when the ovaries, hypothalamus, pancreas, liver and adipose tissue are being organized.

The placenta sits at the center of this proposed pathway. It is not a passive conduit but an endocrine, immune, vascular and nutrient-sensing organ that interprets maternal metabolic signals, including glucose, lipids, insulin, cytokines, oxygen and hormones, and regulates fetal exposure to them. In pregnancies complicated by obesity, placental function can be altered through inflammation, oxidative stress, mitochondrial dysfunction, changes in lipid transport and disrupted steroid metabolism. Recent single-cell and transcriptional studies of the placenta support the idea that obesity alters the maternal-fetal interface through nutrient transport and developmental signaling, though the review notes that placental adaptations are not always harmful and can sometimes support fetal growth.

One of the most concrete mechanistic threads involves insulin and androgens. Insulin resistance is a central feature of many forms of the syndrome: it stimulates theca cells in the ovary to produce androgen precursors and suppresses hepatic production of sex hormone-binding globulin, which raises the fraction of free, biologically active androgen in circulation. The hyperinsulinemia associated with excessive gestational weight gain could operate through the same lever in pregnancy, potentially increasing fetal exposure to free androgens.

The review also details how fetal ovarian development could be affected. The fetal ovary progresses through germ-cell proliferation, meiosis, nest breakdown and primordial follicle formation, and it responds to the nutrient and lipid supply provided by the mother. Excess maternal nutrition and lipid could shift reactive oxygen species production, antioxidant defenses and stromal cell numbers. Anti-Müllerian hormone, a key regulator of follicular recruitment, is often elevated in the syndrome and actively promotes follicular arrest. Experimental work in mice suggests that elevated maternal AMH during pregnancy can alter the fetal endocrine environment and produce syndrome-like reproductive and neuroendocrine traits in female offspring, though whether this operates in humans remains untested.

Puberty emerges as the moment when any such prenatal programming would become visible. The pubertal transition normally involves a temporary rise in insulin resistance, maturation of gonadotropin pulsatility, increased ovarian steroid production and fat redistribution. In an adolescent whose metabolic and ovarian systems were already shaped by the intrauterine environment, these same physiological changes could unmask an existing liability, presenting as hyperandrogenism, irregular or absent periods, hirsutism or acne. The authors frame puberty not as the initiating event in the disorder but as the stage at which earlier endocrinologically programmed changes become clinically apparent.

The review is equally explicit about what the evidence does not show. Human studies have linked maternal metabolic conditions and the syndrome itself to selected offspring outcomes, but they provide limited evidence that excessive gestational weight gain independently predicts the syndrome in daughters. Observational research struggles to disentangle intrauterine effects from shared genetic predisposition, maternal obesity, gestational diabetes, socioeconomic factors and the postnatal environment, including diet and activity patterns. The authors also draw a sharp line between intergenerational and transgenerational effects: when a pregnant woman is exposed, her fetus and the germ cells within that fetus are directly affected, so abnormalities seen in the first or second generation cannot by themselves demonstrate true transgenerational inheritance, which would require effects to persist into a first unexposed generation, typically the third.

On the epigenetic front, the review surveys mechanisms that could carry a gestational exposure forward in time. DNA methylation, histone modifications, chromatin remodeling, microRNAs and other non-coding RNAs carried in gametes, and mitochondrial dysfunction are all candidate carriers of endocrine memory. Recent experimental evidence indicates that males can transmit metabolic and reproductive risk through sperm-derived small non-coding RNAs, with phenotypes appearing mainly in female descendants. But the authors conclude that these findings provide biological plausibility rather than proof, and that no case of transgenerational inheritance in humans has been established for this exposure.

Practically, the authors urge caution against maternal blame and against overpromising prevention. They suggest that preconception and early pregnancy offer windows to assess metabolic risk, including weight, glycemic status, lipids and reproductive history, and that routine pediatric care can monitor daughters’ growth, pubertal development and signs of androgen excess without implying that any intervention has been shown to prevent the syndrome. They call for prospective mother-daughter cohorts that begin before conception or early in pregnancy, include repeated metabolic and hormonal measures, incorporate placental profiling, and follow offspring through puberty and into adulthood. Until such studies are done, the question of whether excessive gestational weight gain leaves a legacy in daughters remains an open and testable hypothesis rather than a settled fact.

Subject of Research: Developmental and transgenerational programming of polyendocrine metabolic ovarian syndrome risk by excessive gestational weight gain

Article Title: Is polyendocrine metabolic ovarian syndrome a legacy of excessive gestational weight gain? A review of developmental and transgenerational programming

Article References: Ge, Z., Wang, J., & Zhang, C. (2026). Is polyendocrine metabolic ovarian syndrome a legacy of excessive gestational weight gain? A review of developmental and transgenerational programming. Frontiers in Endocrinology, 17, Article 1978407. https://doi.org/10.3389/fendo.2026.1978407

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1978407

Keywords: polycystic ovary syndrome, polyendocrine metabolic ovarian syndrome, gestational weight gain, fetal programming, placental biology, insulin resistance, hyperandrogenism, epigenetic inheritance, puberty, maternal obesity, HPO axis, developmental endocrinology